Skip to content
Company Analysis

Evotec SE EVO

A comprehensive view of key metrics, scores, and financial health for Evotec SE

Overview of Evotec SE

EVO NMS
Healthcare Drug Manufacturers - Specialty & Generic Framework: Pharma / Mature Biotech Small Cap
Evotec SE (EVO), is a Small Cap company, in the Drug Manufacturers - Specialty & Generic industry, last closed at $1.52, about 180.9% undervalued vs fair value, -54.1% 1Y return, ranked 864/1145 in sector.
Metrics Rev Growth -1.1% ROE -11.7% Gross Margin 14.5% Div Yield 0.00%
USD 1.52
-0.65%
(Delayed)
• Vol 90d: 55.1%
52-Week Range
Market Cap
$559.05M
Enterprise Value
$702.50M
Overall Score
View breakdown
Overall
Growth
Weak
Profitability
Fair
Health
Fair
Efficiency
Fair
Valuation
Weak
Growth
Weak
Profitability
Fair
Health
Fair
Efficiency
Fair
Valuation
Weak
Completeness: 100%
Confidence: 97%
Updated: Oct 31
Top Beats

Quick Facts

Website https://www.evotec.com
HQ Hamburg
Employees 4,788
Fiscal year Dec 31

Next Events

Earnings Nov 5

Fair Value Snapshot

Bear Base Bull
$4
$4
$5
Current: $1.52 +181% vs base

Engine Room Money Flow™

Small Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
EUR 788.4M
-1.1%%
Gross Profit
EUR 114.2M
-0.6%%
R&D Expense
EUR 37.5M
-26.2%%
Operating Income (EBIT)
-EUR 72.3M
60.3%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

R&D Intensity
4.8%
Fair

Lower R&D intensity - may indicate mature portfolio or cost cuts

Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

EUR 1.5M

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
3
Active Leaks
1/3
Improving
0
High Impact
3
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Evotec SE's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
47
/100
Developing
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Revenue Growth Consistent Revenue growth volatility is low (stability score 0.76), suggesting sticky customer base.
  • Margins Stable Across Cycles Operating margin volatility is low (stability score 0.80), demonstrating pricing resilience across cycles.

Key risks

  • Scale Without Profitability Despite scale, profitability lags peers (score 0.31), suggesting limited competitive advantage.
  • Inconsistent Cash Generation Cash generation is inconsistent (score 0.45), indicating operational challenges.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
41
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

vs Industry Peers 95% Coverage
Trade-Off Triangle Visualization A ternary plot showing EVO's balance between Growth (31.9%), Profitability (30.4%), and Safety (37.7%). Growth 32% Safety 38% Profitability 30%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

41th percentile vs peers
41
Key Signals
Rev Growth YoY -1.1% 37p Revenue CAGR 3Y 1.6% 41p EPS Growth YoY 47.3% 51p TSR -26.0% 34p
Strengths
  • Debt/FCF Ratio in top 20% of peers (-4.64, 95th percentile)
  • Strong liquidity position vs peers
Risks

No significant risks identified for this axis.

Profitability

39th percentile vs peers
39
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

48th percentile vs peers
49
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Evotec SE.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$4.27
- - -
+180.9% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000